- Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit StudyCai, Qingqing; Liu, Panpan; Xia, Yi; Cai, Jun; Huang, Huiqiang; Li, Zhiming; Zhou, Hui; Li, Yajun; Wang, Hanyu; Huang, Ying; Yan, Gao; Pan, Xueyi64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 3
- Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.Bachy, Emmanuel; Savage, Kerry J.; Huang, Huiqiang; Kwong, Yok-Lam; Gritti, Giuseppe; Zhang, Qingyuan; Liberati, Anna Marina; Cao, Junning; Yang, Haiyan; Hao, Siguo; Hu, Jianda; Zhou, Keshu; Russo, Filomena; Zhang, Huilai; Sang, Wei; Ji, Jie; Liu, Hui; Huang, Sha; Zinzani, Pier LuigiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 3
- Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trialHuang, Y.; Wu, T.; Hu, Y.; Li, Y.; Ma, J.; Guo, Y.; Zhou, H.; Yang, R.; Gong, Y.; Zhang, Q. Y.; Lin, L. E.; Zhou, R.; Liu, Y.; Pan, Z.; Xue, J.; Wang, D.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
会议论文
PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study
5阅读
